Akebia Therapeutics, Inc. (AKBA)

1,3700 0,0000 (0,00%) Alla chiusura: 04:00PM EDT

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098
https://www.akebia.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 167

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John P. Butler MBA	CEO, President, Interim Principal Financial Officer & Director	1,29M	N/D	1964
Mr. Michel Dahan	Senior VP & COO	734,73k	N/D	1979
Ms. Nicole R. Hadas J.D.	Senior VP, Chief Legal Officer & Secretary	687,38k	N/D	1973
Dr. Steven Keith Burke M.D.	Senior VP of Research & Development and Chief Medical Officer	766,57k	N/D	1961
Mr. Richard C. Malabre	Chief Accounting Officer	N/D	N/D	1961
Ms. Kimberly Garko	Senior VP & Chief Technical Officer	N/D	N/D	N/D
Tracey Vetterick	Vice President of Portfolio Strategy & Corporate Administration	N/D	N/D	N/D
Mercedes Carrasco	Director of Corporate Communications	N/D	N/D	N/D
Ms. Meredith Bowman	Senior VP & Chief People Officer	N/D	N/D	N/D
Ms. Carolyn Rucci	Senior Vice President of Legal & General Counsel	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Akebia Therapeutics, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.